Cantargia presents update on the CANFOUR clinical trial and phase IIa preparations
· 15 patients treated and CAN04 showed a good safety profile · A few more patients to be included to establish maximum tolerated or recommended dose · The phase IIa part of the study to start in Q4 2018 Cantargia AB today announced the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial.So far, 15 patients have received therapy in the phase I safety part of the study, and generally the immuno-oncology antibody CAN04, targeting IL1RAP, has been well tolerated. Notably,